Frazier Life Sciences Public Fund, L.P. - Significant Ownership

Signature - Title
Frazier Life Sciences Public Fund, L.P. - Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.
Location
Palo Alto, CA
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by Frazier Life Sciences Public Fund, L.P..

Significant Ownership of Frazier Life Sciences Public Fund, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
TRVI Trevi Therapeutics, Inc. Common Stock 11.9% $64.7M 10.7M James N. Topper Dec 31, 2024
MAZE Maze Therapeutics, Inc. Common Stock, par value $0.001 per share 7.3% $36.1M 3.19M James N. Topper Feb 3, 2025
MREO Mereo BioPharma Group plc Ordinary Shares, nominal value EURO0.003 per share, represented by American Depository Shares 5.1% $101M 40.3M James N. Topper Apr 1, 2025
PVLA Palvella Therapeutics, Inc. Common Stock 5.1% $16.7M 576K James N. Topper Dec 13, 2024
ELDN Eledon Pharmaceuticals, Inc. Common Stock 2% $5.53M 1.18M James N. Topper Dec 31, 2024
ANAB AnaptysBio, Inc. Common Stock 0.5% Frazier Life Sciences Public Fund, L.P. Jan 31, 2025
PBYI Puma Biotechnology, Inc. Common Stock 0% $0 0 Frazier Life Sciences Public Fund, L.P. Dec 31, 2024
ANTX AN2 THERAPEUTICS, INC. Common Stock 0% $0 0 Frazier Life Sciences Public Fund, L.P. Dec 31, 2024

Schedules 13D/G Reported by Frazier Life Sciences Public Fund, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Date Filed
* An asterisk sign (*) next to the price indicates that the price is likely invalid.